Six-month versus 24-month dual antiplatelet therapy after implantation of drug eluting stents in patients non-resistant to aspirin: ITALIC, a randomized multicenter trial

Martine Gilard , MD, PhD, Paul Barragan , MD, Arif AL. Noryani , MD, Hussam A. Noor , MD, Talib Majwal , MD, Thomas Hovasse , MD, Philippe Castellant , MD, Michel Schneeberger , MD, Luc Maillard , MD, PhD, Erwan Bressolette E , MD, Jaroslaw Wojcik , MD, Nicolas Delarche , MD, Didier Blanchard , MD, Bernard Jouve , MD, Olivier Ormezzano , MD, Franck Paganelli , MD, Gilles Levy , MD, Joel Sainsous , MD, Didier Carrie , MD, Alain Furber , MD, PhD, Jacques Berland , MD, Oliver Darremont , MD, Herve Le Breton , MD, Anne Lyuycx-Bore , MD, Antoine Gommeaux , MD, Claude Cassat , MD, Alain Kermarrec , MD, Pierre Cazaux , MD, Philippe Druelles , MD, Raphael Dauphin , MD, Jean Armengaud , MD, Patrick Dupouy , MD, Didier Champagnac , MD, Patrick Ohlmann , MD, Knut Endresen K , MD, Hakim Benamer , MD, Robert Gabor Kiss , MD, Imre Ungi , MD, Jacques Boschat J , MD, Marie-Claude Morice , MD

[1]  E. Vicaut,et al.  Dual-antiplatelet treatment beyond 1 year after drug-eluting stent implantation (ARCTIC-Interruption): a randomised trial , 2014, The Lancet.

[2]  Helmut Baumgartner,et al.  2014 ESC/EACTS Guidelines on myocardial revascularization: the Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). Developed with the special contribution of the European Association of Percutaneous , 2014, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.

[3]  S. Silber,et al.  Lack of association between dual antiplatelet therapy use and stent thrombosis between 1 and 12 months following resolute zotarolimus-eluting stent implantation. , 2014, European heart journal.

[4]  G. Stone,et al.  Clinical outcomes with bioabsorbable polymer- versus durable polymer-based drug-eluting and bare-metal stents: evidence from a comprehensive network meta-analysis. , 2014, Journal of the American College of Cardiology.

[5]  Deepak L. Bhatt,et al.  Three vs twelve months of dual antiplatelet therapy after zotarolimus-eluting stents: the OPTIMIZE randomized trial. , 2013, JAMA.

[6]  P. Serruys,et al.  Safety and efficacy of drug-eluting stents in women: a patient-level pooled analysis of randomised trials , 2013, The Lancet.

[7]  Mario Fusaro,et al.  Bare metal stents, durable polymer drug eluting stents, and biodegradable polymer drug eluting stents for coronary artery disease: mixed treatment comparison meta-analysis , 2013, BMJ.

[8]  Peter L Duffy,et al.  Platelet reactivity and clinical outcomes after coronary artery implantation of drug-eluting stents (ADAPT-DES): a prospective multicentre registry study , 2013, The Lancet.

[9]  A. Kastrati,et al.  Clinical impact of extended dual antiplatelet therapy after percutaneous coronary interventions in the drug-eluting stent era: a meta-analysis of randomized trials. , 2012, European heart journal.

[10]  Y. Jang,et al.  A new strategy for discontinuation of dual antiplatelet therapy: the RESET Trial (REal Safety and Efficacy of 3-month dual antiplatelet Therapy following Endeavor zotarolimus-eluting stent implantation). , 2012, Journal of the American College of Cardiology.

[11]  P. Serruys,et al.  Stent thrombosis: insights on outcomes, predictors and impact of dual antiplatelet therapy interruption from the SPIRIT II, SPIRIT III, SPIRIT IV and COMPARE trials. , 2012, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.

[12]  Deepak L. Bhatt,et al.  Short- and Long-Term Outcomes With Drug-Eluting and Bare-Metal Coronary Stents: A Mixed-Treatment Comparison Analysis of 117 762 Patient-Years of Follow-Up From Randomized Trials , 2012, Circulation.

[13]  P. Serruys,et al.  Biodegradable polymer drug-eluting stents reduce the risk of stent thrombosis at 4 years in patients undergoing percutaneous coronary intervention: a pooled analysis of individual patient data from the ISAR-TEST 3, ISAR-TEST 4, and LEADERS randomized trials. , 2012, European heart journal.

[14]  G. Stone,et al.  Drug-eluting vs bare-metal stents in primary angioplasty: a pooled patient-level meta-analysis of randomized trials. , 2012, Archives of internal medicine.

[15]  G. Stone,et al.  Stent thrombosis with drug-eluting and bare-metal stents: evidence from a comprehensive network meta-analysis , 2012, The Lancet.

[16]  Marco Valgimigli,et al.  Comparison of drug-eluting stents with bare metal stents in patients with ST-segment elevation myocardial infarction. , 2012, European heart journal.

[17]  J. Marchesini,et al.  Short- Versus Long-Term Duration of Dual-Antiplatelet Therapy After Coronary Stenting: A Randomized Multicenter Trial , 2012, Circulation.

[18]  M. Jeong,et al.  Six-Month Versus 12-Month Dual Antiplatelet Therapy After Implantation of Drug-Eluting Stents: The Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting (EXCELLENT) Randomized, Multicenter Study , 2012, Circulation.

[19]  G. Levine,et al.  2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. , 2011, Circulation.

[20]  F. Eberli,et al.  Long-term clinical outcomes of biodegradable polymer biolimus-eluting stents versus durable polymer sirolimus-eluting stents in patients with coronary artery disease (LEADERS): 4 year follow-up of a randomised non-inferiority trial , 2011, The Lancet.

[21]  P. Smits,et al.  The SPIRIT V Study A Clinical Evaluation of the XIENCE V Everolimus-Eluting Coronary Stent System in the Treatment of Patients With De Novo Coronary Artery Lesions , 2011 .

[22]  M. Jeong,et al.  Duration of dual antiplatelet therapy after implantation of drug-eluting stents. , 2010, The New England journal of medicine.

[23]  P. Serruys,et al.  Myocardial infarction adjudication in contemporary all-comer stent trials: balancing sensitivity and specificity. Addendum to the historical MI definitions used in stent studies. , 2010, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.

[24]  Claes Held,et al.  Ticagrelor versus clopidogrel in patients with acute coronary syndromes. , 2009, The New England journal of medicine.

[25]  E. Antman,et al.  Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial , 2009, The Lancet.

[26]  W Scott Beattie,et al.  Aspirin “resistance” and risk of cardiovascular morbidity: systematic review and meta-analysis , 2008, BMJ : British Medical Journal.

[27]  Simon Wandel,et al.  Outcomes associated with drug-eluting and bare-metal stents: a collaborative network meta-analysis , 2007, The Lancet.

[28]  Justin T. Newcomer,et al.  Evaluation of Dose-Related Effects of Aspirin on Platelet Function: Results From the Aspirin-Induced Platelet Effect (ASPECT) Study , 2007, Circulation.

[29]  P. Serruys,et al.  Clinical End Points in Coronary Stent Trials: A Case for Standardized Definitions , 2007, Circulation.

[30]  Seung‐Jung Park,et al.  Serial intravascular ultrasound evidence of both plaque stabilization and lesion progression in patients with ruptured coronary plaques: effects of statin therapy on ruptured coronary plaque. , 2007, Atherosclerosis.

[31]  Neville Kukreja,et al.  Early and late coronary stent thrombosis of sirolimus-eluting and paclitaxel-eluting stents in routine clinical practice: data from a large two-institutional cohort study , 2007, The Lancet.

[32]  C. Grines,et al.  Prevention of premature discontinuation of dual antiplatelet therapy in patients with coronary artery stents: a science advisory from the American Heart Association, American College of Cardiology, Society for Cardiovascular Angiography and Interventions, American College of Surgeons, and American D , 2007, Journal of the American College of Cardiology.

[33]  P. Serruys,et al.  Sirolimus- vs paclitaxel-eluting stents in de novo coronary artery lesions: the REALITY trial: a randomized controlled trial. , 2006, JAMA.

[34]  M. Buchanan Biological basis and clinical implications of acetylsalicylic acid resistance. , 2006, The Canadian journal of cardiology.

[35]  F. Eberli,et al.  Sirolimus-eluting and paclitaxel-eluting stents for coronary revascularization. , 2005, The New England journal of medicine.

[36]  G. Finet,et al.  Evolution of Spontaneous Atherosclerotic Plaque Rupture With Medical Therapy: Long-Term Follow-Up With Intravascular Ultrasound , 2004, Circulation.

[37]  G. Stone,et al.  A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease. , 2004, The New England journal of medicine.

[38]  Jeffrey W Moses,et al.  Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. , 2003, The New England journal of medicine.

[39]  E. Topol,et al.  A prospective, blinded determination of the natural history of aspirin resistance among stable patients with cardiovascular disease. , 2003, Journal of the American College of Cardiology.

[40]  Eric J Topol,et al.  Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. , 2002, JAMA.

[41]  S. Yusuf,et al.  Aspirin-Resistant Thromboxane Biosynthesis and the Risk of Myocardial Infarction, Stroke, or Cardiovascular Death in Patients at High Risk for Cardiovascular Events , 2002, Circulation.

[42]  R. Califf,et al.  Acute Coronary Syndromes in the GUSTO-IIb Trial Prognostic Insights and Impact of Recurrent Ischemia , 1998 .

[43]  U. Losert,et al.  Variable Platelet Response to Low-dose ASA and the Risk of Limb Deterioration in Patients Submitted to Peripheral Arterial Angioplasty , 1997, Thrombosis and Haemostasis.

[44]  Walker,et al.  Collaborative overview of randomised trials of antiplatelet therapy Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients , 1994 .

[45]  K. Mann,et al.  Hemorrhagic events during therapy with recombinant tissue-type plasminogen activator, heparin, and aspirin for acute myocardial infarction. Results of the Thrombolysis in Myocardial Infarction (TIMI), Phase II Trial. , 1991, Annals of internal medicine.

[46]  E. Kaplan,et al.  Nonparametric Estimation from Incomplete Observations , 1958 .

[47]  P. Gurbel The relationship of platelet reactivity to the occurrence of post-stenting ischemic events: emergence of a new cardiovascular risk factor. , 2006, Reviews in cardiovascular medicine.

[48]  S. Anand Aspirin-resistant thromboxane biosynthesis and the risk of myocardial infarction, stroke, or cardiovascular death in patients at high risk for cardiovascular events. Eikelboom JW, Hirsh J, Weitz J, Johnston M, Yi Q, Yusuf S. Circulation 2002; 105: 1650- 1655. , 2002 .

[49]  D. Cox Regression Models and Life-Tables , 1972 .